-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Adaptimmune Therapeutics PLC quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2014 to 2023.
- Adaptimmune Therapeutics PLC Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was $526K, a 22.6% decline year-over-year.
- Adaptimmune Therapeutics PLC Income Tax Expense (Benefit) for the twelve months ending June 30, 2024 was $1.08M, a 59.9% decline year-over-year.
- Adaptimmune Therapeutics PLC annual Income Tax Expense (Benefit) for 2023 was $1.34M, a 46.5% decline from 2022.
- Adaptimmune Therapeutics PLC annual Income Tax Expense (Benefit) for 2022 was $2.5M, a 216% increase from 2021.
- Adaptimmune Therapeutics PLC annual Income Tax Expense (Benefit) for 2021 was $791K, a 388% increase from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)